397 related articles for article (PubMed ID: 27003946)
1. Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis.
Novakova L; Axelsson M; Khademi M; Zetterberg H; Blennow K; Malmeström C; Piehl F; Olsson T; Lycke J
Mult Scler; 2017 Jan; 23(1):62-71. PubMed ID: 27003946
[TBL] [Abstract][Full Text] [Related]
2. Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple sclerosis.
Novakova L; Axelsson M; Khademi M; Zetterberg H; Blennow K; Malmeström C; Piehl F; Olsson T; Lycke J
J Neurochem; 2017 Apr; 141(2):296-304. PubMed ID: 27787906
[TBL] [Abstract][Full Text] [Related]
3. Glial and neuroaxonal biomarkers in a multiple sclerosis (MS) cohort.
Kalatha T; Hatzifilippou E; Arnaoutoglou M; Balogiannis S; Koutsouraki E
Hell J Nucl Med; 2019; 22 Suppl 2():113-121. PubMed ID: 31802051
[TBL] [Abstract][Full Text] [Related]
4. Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis.
Axelsson M; Malmeström C; Gunnarsson M; Zetterberg H; Sundström P; Lycke J; Svenningsson A
Mult Scler; 2014 Jan; 20(1):43-50. PubMed ID: 23702432
[TBL] [Abstract][Full Text] [Related]
5. Cerebrospinal fluid NCAM levels are modulated by disease-modifying therapies.
Axelsson M; Dubuisson N; Novakova L; Malmeström C; Giovannoni G; Lycke J; Gnanapavan S
Acta Neurol Scand; 2019 May; 139(5):422-427. PubMed ID: 30657162
[TBL] [Abstract][Full Text] [Related]
6. Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis.
Axelsson M; Malmeström C; Nilsson S; Haghighi S; Rosengren L; Lycke J
J Neurol; 2011 May; 258(5):882-8. PubMed ID: 21197541
[TBL] [Abstract][Full Text] [Related]
7. Biomarkers of inflammation and axonal degeneration/damage in patients with newly diagnosed multiple sclerosis: contributions of the soluble CD163 CSF/serum ratio to a biomarker panel.
Stilund M; Gjelstrup MC; Petersen T; Møller HJ; Rasmussen PV; Christensen T
PLoS One; 2015; 10(4):e0119681. PubMed ID: 25860354
[TBL] [Abstract][Full Text] [Related]
8. Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod.
Piehl F; Kockum I; Khademi M; Blennow K; Lycke J; Zetterberg H; Olsson T
Mult Scler; 2018 Jul; 24(8):1046-1054. PubMed ID: 28627962
[TBL] [Abstract][Full Text] [Related]
9. Determination of chitinase 3-like 1 in cerebrospinal fluid in multiple sclerosis and other neurological diseases.
Kušnierová P; Zeman D; Hradílek P; Zapletalová O; Stejskal D
PLoS One; 2020; 15(5):e0233519. PubMed ID: 32437412
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of cerebrospinal fluid neurofilament light chain and chitinase-3-like-1 in newly diagnosed patients with multiple sclerosis.
Sellebjerg F; Royen L; Soelberg Sørensen P; Oturai AB; Jensen PEH
Mult Scler; 2019 Oct; 25(11):1444-1451. PubMed ID: 30113249
[TBL] [Abstract][Full Text] [Related]
11. NFL and CXCL13 may reveal disease activity in clinically and radiologically stable MS.
Novakova L; Axelsson M; Malmeström C; Zetterberg H; Blennow K; Svenningsson A; Lycke J
Mult Scler Relat Disord; 2020 Nov; 46():102463. PubMed ID: 32862040
[TBL] [Abstract][Full Text] [Related]
12. Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis.
Kuhle J; Malmeström C; Axelsson M; Plattner K; Yaldizli O; Derfuss T; Giovannoni G; Kappos L; Lycke J
Acta Neurol Scand; 2013 Dec; 128(6):e33-6. PubMed ID: 23763388
[TBL] [Abstract][Full Text] [Related]
13. Glial and neuronal markers in cerebrospinal fluid in different types of multiple sclerosis.
Mañé-Martínez MA; Olsson B; Bau L; Matas E; Cobo-Calvo Á; Andreasson U; Blennow K; Romero-Pinel L; Martínez-Yélamos S; Zetterberg H
J Neuroimmunol; 2016 Oct; 299():112-117. PubMed ID: 27725108
[TBL] [Abstract][Full Text] [Related]
14. Cerebrospinal fluid levels of chitinase 3-like 1 and neurofilament light chain predict multiple sclerosis development and disability after optic neuritis.
Modvig S; Degn M; Roed H; Sørensen TL; Larsson HB; Langkilde AR; Frederiksen JL; Sellebjerg F
Mult Scler; 2015 Dec; 21(14):1761-70. PubMed ID: 25698172
[TBL] [Abstract][Full Text] [Related]
15. Increased cerebrospinal fluid chitinase 3-like 1 and neurofilament light chain in pediatric acquired demyelinating syndromes.
Boesen MS; Jensen PEH; Magyari M; Born AP; Uldall PV; Blinkenberg M; Sellebjerg F
Mult Scler Relat Disord; 2018 Aug; 24():175-183. PubMed ID: 30055504
[TBL] [Abstract][Full Text] [Related]
16. Neurofilament light chain in cerebrospinal fluid and prediction of disease activity in clinically isolated syndrome and relapsing-remitting multiple sclerosis.
Håkansson I; Tisell A; Cassel P; Blennow K; Zetterberg H; Lundberg P; Dahle C; Vrethem M; Ernerudh J
Eur J Neurol; 2017 May; 24(5):703-712. PubMed ID: 28261960
[TBL] [Abstract][Full Text] [Related]
17. Cerebrospinal Fluid Biomarkers in Relation to MRZ Reaction Status in Primary Progressive Multiple Sclerosis.
Robinson T; Abdelhak A; Bose T; Meinl E; Otto M; Zettl UK; Dersch R; Tumani H; Rauer S; Huss A
Cells; 2020 Nov; 9(12):. PubMed ID: 33255854
[TBL] [Abstract][Full Text] [Related]
18. Assessing tissue damage in multiple sclerosis: a biomarker approach.
Burman J; Zetterberg H; Fransson M; Loskog AS; Raininko R; Fagius J
Acta Neurol Scand; 2014 Aug; 130(2):81-9. PubMed ID: 24571714
[TBL] [Abstract][Full Text] [Related]
19. A Score Based on NfL and Glial Markers May Differentiate Between Relapsing-Remitting and Progressive MS Course.
Huss A; Otto M; Senel M; Ludolph AC; Abdelhak A; Tumani H
Front Neurol; 2020; 11():608. PubMed ID: 32765393
[No Abstract] [Full Text] [Related]
20. A comparative study of CSF neurofilament light and heavy chain protein in MS.
Kuhle J; Plattner K; Bestwick JP; Lindberg RL; Ramagopalan SV; Norgren N; Nissim A; Malaspina A; Leppert D; Giovannoni G; Kappos L
Mult Scler; 2013 Oct; 19(12):1597-603. PubMed ID: 23529999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
